• M C Islas-Carbajal, A Covarrubias, G Grijalva, A Alvarez-Rodríguez, J Armendáriz-Borunda, and A R Rincón-Sánchez.
• Instituto de Biología Molecular en Medicina y Terapia Génica. C.U.C.S. U. de G, Mexico, Mexico.
• Liver Int. 2005 Feb 1; 25 (1): 131-40.

UnlabelledNitric oxide (NO) has been implicated in cirrhosis and might be implicated in renal failure end-stage cirrhosis.AimOur aim was to evaluate NO role in renal failure induced during decompensated cirrhosis, using the following inhibitors: aminoguanidine (AG), a specific inducible nitric oxide synthase (iNOS) inhibitor and NG-nitro-l-arginine methyl ester (L-NAME), a nonselective blocker of NOS isoforms.MethodsEndothelial (eNOS) and iNOS gene expression was analyzed by reverse transcriptase-polymerase chain reaction. Cirrhotic rats received a single intragastric dose of CCl(4) to induce acute liver damage (ALD).ResultsAfter ALD, aspartate aminotransferase highest levels were observed in rats treated with AG and ALT in rats treated with L-NAME. Inhibitors decreased creatinine serum levels to normal values and serum sodium levels re-established after the third day of ALD. L-NAME diminished (P<0.05) eNOS RNA renal expression. Renal iNOS with no inhibitor was overexpressed but was down-regulated by AG treatment. Liver eNOS RNA expression had a decreased expression before ALD in cirrhotic rats, but L-NAME treatment down-regulated eNOS after ALD. AG induced an important iNOS liver decrease.ConclusionBoth inhibitors improved renal function, although AG displayed a better effect and did not aggravate liver function. We concluded that NOS isoforms are implicated in the renal pathophysiologic events induced by ALD.

47 keywords...

hide…